Schedule 13G filing

Franklin Templeton Inc disclosed a 6% stake in JBIO

Schedule 13G · Filed Oct 28, 2026

Franklin Templeton Inc reported owning 6% of Jade Biosciences, Inc. (JBIO) (3,807,236 shares) in a Schedule 13G filed Oct 28, 2026.

A 13G is a passive stake: the holder does not plan to push for changes.

Stake

Jade Biosciences, Inc.

Stake

6% stake

Share this trade

From a public Schedule 13G, linked above. Not investment advice, and not a recommendation to buy or sell.